GlassScriptPhysician profile
Ali Asif Khan
NPI 1801320957
$41,584.53
in general payments reported to CMS, 2019-2025
26 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $17.37 · 2023: $801 · 2024: $22K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Travel and Lodging: $7,115 · Food and Beverage: $5,219 · Education: $35.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,000.00 |
| Travel and Lodging | $7,115.46 |
| Food and Beverage | $5,218.97 |
| Education | $35.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $37,220.07 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $975.52 | 2024-2025 | Apollo Esg Nxt System, Overstitch Endoscopic Suturing System, Cre Pro |
| Abbvie INC. | $713.01 | 2021-2025 | |
| Janssen Biotech, INC. | $499.19 | 2024-2025 | Tremfya, Stelara |
| Celgene Corporation | $403.33 | 2023-2024 | Zeposia |
| Pfizer INC. | $366.96 | 2023-2025 | |
| Gilead Sciences, INC. | $221.99 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $178.35 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Genzyme Corporation | $164.26 | 2023-2025 | |
| Novo Nordisk INC | $113.40 | 2023 | |
| Lilly USA, LLC | $109.16 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $77.98 | 2025 | Rezdiffra |
| Celltrion USA INC. | $57.24 | 2023-2024 | Zymfentra |
| Regeneron Healthcare Solutions, INC. | $56.26 | 2022-2023 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $55.13 | 2024-2025 | Iqirvo, Bylvay |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $53.00 | 2024 | Fibroscan |
| Aimmune Therapeutics, INC. | $49.11 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.50 | 2024 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $44.80 | 2025 | |
| Qol Medical, LLC | $38.86 | 2025 | Sucraid |
| Ferring Pharmaceuticals INC. | $37.67 | 2023-2024 | Rebyota |
| Alnylam Pharmaceuticals INC. | $32.21 | 2024-2025 | Givlaari |
| Fresenius Kabi USA, LLC | $18.67 | 2023 | Idacio |
| Organon LLC | $17.93 | 2025 | Renflexis, Hadlima |
| Capsovision, INC. | $16.58 | 2024 | Capsocam Plus |
| Braintree Laboratories, INC. | $16.35 | 2025 | Suflave, Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.